Three Biopharmaceutical Organizations Award $1.7 Million in Studies to eResearchTechnology for Cardiac Safety Monitoring and Inf

Three Biopharmaceutical Organizations Award $1.7 Million in
Studies to eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services
Awards Advance Market Penetration in Early and Late Stage Development 


PHILADELPHIA, April 5  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), , a leading provider of centralized electrocardiographic (ECG) collection
and interpretation services, announced today that it has received agreements for
about $1.7 million in cardiac safety monitoring and services from two fast
growing biotechnology organizations and a mid-market biopharmaceutical
organization for three drug candidates in clinical development.

The agreements cover two extensive Phase I studies and two Phase III studies
that will be conducted at more than 100 sites in North America and Europe.  eRT
will provide comprehensive support including the provision, training and ongoing
assistance required for effective use of 100 standing 12- lead ECG machines and
more than 60 digital 12-lead Holter recorders, which are designed to facilitate
24-hour digital recording of cardiac safety data that is subsequently provided
to eRT for analysis.  eRT will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data through its
EXPeRT workflow enabled data handling technology, the first solution in
production that was designed explicitly to meet emerging international
regulatory guidance and technical standards.

"eRT's vast experience in providing cardiac safety services across all phases of
clinical development will drive value for the fast growing sponsors of these
diverse trials, which range from a Thorough Phase I ECG Study, to a significant
routine Phase I study, to two massively distributed Phase III trials," said
Scott Grisanti, senior vice president of business development and chief
marketing officer at eRT.  "We continue to advance our market penetration with
the signing of two sponsors that represent new customers for eRT as well as
expanding our role with an existing client in its effort to bring a novel
therapy to market."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is also
a leader in providing technology and services to streamline the clinical trials
process by enabling its customers to automate the collection, analysis, and
distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. The sponsors may cancel these agreements at their sole discretion.  As a
result, actual results may differ materially from any financial outlooks stated
herein.  Further information on potential factors that could affect the
company's financial results can be found in the company's Reportson Forms 10-K
and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci of eResearchTechnology, [phone]; or Matt

Hayden of Hayden Communications, [phone], for eResearchTechnology



Web site:  http://www.ert.com/ 

Copyright